The Science of Certainty

Rooted in the Gut-Brain-Axis, Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. 


We offer highly specialized CRO services within the
metabolic space. 


We have longstanding experience leading large target and drug
discovery programs with external partners.

We believe 

CSR as usual is not an option

Corporate Responsibility requires more than just big ideas, it requires a firm financial commitment. Gubra is dedicated to donating 10 percent of our pretax profit to social and environmental activities every year.

Upcoming Events

August 23-25 5th International IPF Summit (virtual conference). Meet up with Gubra scientist and Director Michael Feigh.
August 23-25 Basic Cardiovascular Sciences Scientific Sessions 2021 (virtual meeting). Meet up with Gubra scientist Urmas Roostalu.
See all events


+ 28 May 2021 “From a financial perspective 2020 was a year in top 3 for Gubra. Science-wise, we are talking about a record year in terms of discovery, digitalization, robotization and innovation..." says CEO of Gubra Henrik Blou. Read more
+ 19 March 2021 Gubra wins the EY Entrepreneur of the Year Sustainability Prize 2020. The jury recognizes Gubra for our clear attitude in CSR and active efforts for a better climate. Read more
See all news

Rooted in the Gut-Brain Axis

Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We believe that the next great leap forward in treatment paradigms within obesity, diabetes and related metabolic disorders will be found in the interplay of the gut and the brain.

A better understanding of the gut-brain axis will reveal the aetiology of diabetes, obesity and related metabolic disorders and guide us towards novel future treatments of today’s unmed medical needs.

Latest blockbuster webinars

Webinar: Preclinical drug discovery in NASH – Narrowing the translational gap

In this webinar Principal Scientist at Gubra Henrik Björk Hansen discusses strategies to improve clinical translatability of preclinical models of NASH. The webinar introduces a diet-induced obese and biopsy-confirmed rodent model of NASH with progressive development of fibrosis and hepatocellular carcinoma, that recapitulates the wide spectrum of the human condition. 

Play webinar

Release time and duration: February 2021, 26 minutes

Webinar: Lost in translation – how to improve the translatability of rodent models of diabetic kidney disease

Senior scientist Mette Viberg Østergaard introduces to the challenges of using current rodent models of diabetic kidney disease in drug discovery and development. Mette then presents an example of how translatability may be improved in a model of diabetic kidney disease in the setting of type 2 diabetes and hypertension.

Play webinar

Release time and duration: November 2020, 23 minutes

Webinar: Imaging diabetes using light sheet microscopy

In this webinar, principal scientist and biologist Jacob Hecksher-Sørensen talks about how to label the beta cells and image the whole pancreas, how to quantify the beta cell volume in mouse models of Type 1 and Type 2 diabetes, and lastly, Jacob takes us down new avenues imaging the nerves and vasculature.

Play webinar

Release time and duration: October 2020, 17 minutes

Do you want to be part of a great team aiming high? Join us.

Our ambition is that Gubra is a place where talented people are empowered to put their competencies and passion into play every day. We work as a team to make a difference for people with serious metabolic diseases.